Table 1.
Baseline characteristics of the patients
| Variable | Control arm | Treatment arm |
|---|---|---|
| Total (male/female) | 20 (11/9) | 21 (11/10) |
| Median age–years (range) | 61 (48–76) | 54 (24–81) |
| Primary site | ||
| Extremities | 10 | 14 |
| Trunk | 4 | 2 |
| Head and neck | 3 | 1 |
| Acral | 0 | 2 |
| Unknown primary | 3 | 2 |
| Ulceration of primary melanoma | 5 | 7 |
| AJCC stage | ||
| IIIB | 2 | 4 |
| IIIC | 14 | 13 |
| IV-M1a | 1 | 0 |
| IV-M1b | 3 | 3 |
| IV-M1c | 0 | 1 |
| Prior therapy | ||
| Surgery | 20 | 21 |
| Adjuvant radiotherapy | 5 | 4 |
| Immunotherapy | ||
| Adjuvant high-dose IFN-α-2b | 1 | 3 |
| DC-vaccination | 0 | 1 |
| Mage.A3/AS15 peptide vaccine | 0 | 1 |
| BRAF V600 Mutation | ||
| Yes | 11 | 10 |
| No | 6 | 7 |
| Unknown | 3 | 4 |